Mechano-growth factor E peptide inhibits the differentiation and mineralization of osteoblasts.
Xin. Chen C; Bingbing. Zhang Z; Yuanliang. Wang W; Chengyu. Xian X; Li. Yang Y; Moyuan. Deng D; Qin. Peng P; Yuxiao. Li L
Key Findings
- MGF‑E (1 nM) reduced alkaline phosphatase activity, a marker of osteoblast differentiation.
- It lowered collagen I production but increased osteopontin levels.
- Erk pathway activation was necessary for these effects; blocking Erk with PD98059 reversed them.
- MGF‑E raised total Cbfα‑1 protein but prevented its movement into the nucleus, dampening bone‑forming signals.
- Overall mineral deposition (bone nodule formation) was delayed when cells were treated with MGF‑E.
Practical Outcomes
- For biohackers, the take‑away is that using MGF‑E could impair bone health rather than enhance it, so it’s not a useful supplement for strength or longevity goals that depend on strong bones. If you’re experimenting with IGF‑1 variants, be aware that the 24‑aa MGF‑E fragment may counteract bone formation, especially at low nanomolar doses. Monitoring bone turnover markers or avoiding this peptide when bone density is a concern would be prudent.
Summary
The study found that a short piece of the IGF‑1‑related peptide called MGF‑E blocks bone‑building cells (osteoblasts) from maturing and laying down mineral, mainly by turning on the Erk signaling pathway and keeping a key bone‑gene regulator (Cbfα‑1) out of the cell nucleus.
Abstract
To investigate the effects of mechano-growth factor E (MGF-E) peptide derived from an IGF-1 isoform on the differentiation and mineralization of osteoblasts. MGF-E peptide corresponding to the carboxy terminal 24 amino acid peptide of human MGF was synthesized. MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1. At predetermined times, alkaline phosphatase (ALP) activity was quantified using an enzyme activity assay kit. The expression levels of collagen I (Col I) and osteopontin (OPN), and core binding factor 1 (Cbfα-1) were detected by reverse transcription polymerase chain reaction and Western blot analysis. The effect of MGF-E on mineralization was determined by Alizarin Red staining and calcium concentration analysis. The kinase inhibitor PD98059 was used to investigate Erk pathway involvement in the MGF-E role. In the MGF-E-treated osteoblasts, ALP activity decreased with increased Erk activation. The transcription and translation of Col I were inhibited, but those of OPN were enhanced. PD98059 abolished the inhibitory effect and increased the expression of Col I, but decreased that of OPN. Treatment with MGF-E alone up-regulated the mRNA and total protein levels of Cbfα-1, but decreased the fraction of activated Cbfα-1 in the nucleus. Mineralization was delayed by MGF-E, as shown by the bone nodule staining and calcium concentration analysis. These delayed actions were weakened after treatment with PD98059. MGF-E could inhibit osteoblast differentiation and mineralization. The possible mechanisms are increased Erk activity and decreased Cbfα-1 nuclear translocation.
Study Information
pubmed
2011
2011-12-18T00:00:00.000Z
10.1016/j.archoralbio.2011.11.016
18
31